Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders.
Lia A. Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, Elena Zamagni, Jesus D. Aquerreta, Charles L. Roche, Suzanne Lentzsch, Philippe Moreau, Michele Cavo, Jesus San Miguel, Meletios A. Dimopoulos, S. Vincent Rajkumar, Brian G. M. Durie, Evangelos Terpos & Stefan Delorme
Blood Cancer Journal volume 8, Article number: 95 (2018)